|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 4550 Montgomery Avenue |
Address2 | Suite 1100N |
| City | Bethesda |
State | MD |
Zip Code | 20814 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 60195-12
|
||||||||
|
6. House ID# 353460000
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Joel Aurora, Attorney & Agent |
Date | 10/20/2026 5:26:02 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS
H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS
H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS
S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS
S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS
S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS
GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS
GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM
GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS-2454-IFC
GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HIGH-DEDUCTIBLE HEALTH PLANS (HDHPs) PAIRED WITH HEALTH SAVINGS ACCOUNTS (HSAs)
GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS)
GENERAL DISCUSSION ON DRUG PRICING REFORM
GENERAL DISCUSSION ON HEALTH COVERAGE REFORM
GENERAL DISCUSSIONS ON PHARMACY BENEFIT MANAGERS (PBMs) REFORM INCLUDING TRANSPARENCY AND ACCOUNTABILITY, SPREAD PRICING AND PRICE-LINKED COMPENSATION
GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH
GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL RECONCILIATION LEGISLATION
CFF SUBMITS COMMENTS TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) IN RESPONSE TO THEIR REQUEST FOR INFORMATION ON THE AFFORDABLE CARE ACT'S (ACA) ESSENTIAL HEALTH BENEFITS
CFF SUBMITS COMMENTS IN RESPONSE TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) AND CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) REQUEST FOR INFORMATION ON HOW TO IMPLEMENT PBM MEASURES INCLUDED IN THE LAST CONSOLIDATED APPROPRIATIONS ACT
CFF SUBMITS COMMENTS IN RESPONSE TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) INTERIM FINAL RULE ON THE MEDICAID WORK REPORTING REQUIREMENTS
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MARY |
DWIGHT |
|
|
|
DAVID |
ELIN |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code INS
16. Specific lobbying issues
H.R. 6423: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS
S. 864: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS
GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM
GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS-2454-IFC
GENERAL DISCUSSIONS SURROUNDING NON-COMPREHENSIVE INSURANCE PRODUCTS, EXPANSION OF HIGH-DEDUCTIBLE HEALTH PLANS (HDHPs) PAIRED WITH HEALTH SAVINGS ACCOUNTS (HSAs)
GENERAL DISCUSSION ON ALTERNATIVE FUNDING PROGRAMS (AFPS)
GENERAL DISCUSSION ON DRUG PRICING REFORM
GENERAL DISCUSSION ON HEALTH COVERAGE REFORM
GENERAL DISCUSSIONS ON PHARMACY BENEFIT MANAGERS (PBMs) REFORM INCLUDING TRANSPARENCY AND ACCOUNTABILITY, SPREAD PRICING AND PRICE-LINKED COMPENSATION
GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH
GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL RECONCILIATION LEGISLATION
CFF SUBMITS COMMENTS TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) IN RESPONSE TO THEIR REQUEST FOR INFORMATION ON THE AFFORDABLE CARE ACT'S (ACA) ESSENTIAL HEALTH BENEFITS
CFF SUBMITS COMMENTS IN RESPONSE TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) AND CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) REQUEST FOR INFORMATION ON HOW TO IMPLEMENT PBM MEASURES INCLUDED IN THE LAST CONSOLIDATED APPROPRIATIONS ACT
CFF SUBMITS COMMENTS IN RESPONSE TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) INTERIM FINAL RULE ON THE MEDICAID WORK REPORTING REQUIREMENTS
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
DAVID |
ELIN |
|
|
|
MARY |
DWIGHT |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH
GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL RECONCILIATION LEGISLATION
GENERAL DISCUSSION OPPOSING OFFICE OF MANAGEMENT AND BUDGET'S (OMB) PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE (RELEASED 5/29/26)
GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; PROVISIONS RELATED TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) AND RELATED AGENCIES, FOOD AND DRUG ADMINISTRATION (FDA) AND RELATED AGENCIES, CENTERS FOR DISEASE CONTROL AND PREVENTION AND RELATED AGENCIES, NATIONAL INSTITUTES OF HEALTH (NIH) AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
DAVID |
ELIN |
|
|
|
MARY |
DWIGHT |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
H.R. 2902: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS
H.R 7352: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS
S. 1406: SUPPLEMENTAL OXYGEN ACCESS REFORM (SOAR) ACT OF 2025; ALL PROVISIONS
S. 4875: PIONEERING ANTIMICROBIAL SUBSCRIPTIONS TO END UPSURGING RESISTANCE (PASTEUR) ACT OF 2026; ALL PROVISIONS
(DRAFT) CLINICAL TRIAL MODERNIZATION ACT; ALL PROVISIONS
GENERAL DISCUSSIONS SURROUNDING ANTIBIOTICS REIMBURSEMENT AND INCENTIVIZING THE DEVELOPMENT OF NOVEL ANTIMICROBIALS
GENERAL DISCUSSION ON FY2027 APPROPRIATIONS; PROVISIONS RELATED TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) AND RELATED AGENCIES, FOOD AND DRUG ADMINISTRATION (FDA) AND RELATED AGENCIES, CENTERS FOR DISEASE CONTROL AND PREVENTION AND RELATED AGENCIES, NATIONAL INSTITUTES OF HEALTH (NIH) AND RELATED AGENCIES, OBLIGATE STABLE PACE OF SPENDING FY26 FUNDS
GENERAL DISCUSSIONS SURROUNDING RESTRICTIONS ON ADVANCE FUNDING FOR MULTI-YEAR NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH GRANTS; PROVISIONS RELATED TO PRESERVING THE LANGUAGE RESTRICTING ADVANCE FUNDING OF MULTI-YEAR RESEARCH GRANTS BY THE NIH
GENERAL DISCUSSION OPPOSING OFFICE OF MANAGEMENT AND BUDGET'S (OMB) PROPOSED RULE, REGULATION FOR FEDERAL FINANCIAL ASSISTANCE (RELEASED 5/29/26)
CFF SUBMITS COMMENTS TO ORGAN PROCUREMENT & TRANSPLANT NETWORK (OPTN)/HEALTH RESOURCES & SERVICES ADMINISTRATION (HRSA) IN RESPONSE TO OPTN'S UPDATE ON LUNG CONTINUOUS DISTRIBUTION POLICY PROPOSAL
CFF SUBMITS COMMENTS IN RESPONSE TO A REQUEST FOR INFORMATION (RFI) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) ON EXPEDITED INVESTIGATIONAL NEW DRUG PILOT PROGRAM
CFF SUBMITS COMMENTS TO DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) IN RESPONSE TO PROPOSED REGULATION ON CLINICAL TRIALS
CFF SUBMITS COMMENT TO FOOD AND DRUG ADMINISTRATION (FDA) IN RESPONSE TO DRAFT GUIDANCE ON LEVERAGING PRIOR KNOWLEDGE IN THE DEVELOPMENT OF HUMAN GENE THERAPY PRODUCTS INCORPORATING GENOME EDITING
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health Resources & Services Administration (HRSA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MARY |
DWIGHT |
|
|
|
DAVID |
ELIN |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
GENERAL DISCUSSIONS SURROUNDING MAINTAINING ACCESS TO MEDICAID AND PROPOSED CHANGES TO THE PROGRAM
GENERAL DISCUSSIONS ON NEW MEDICAID WORK REPORTING REQUIREMENTS AND DEFINITION OF MEDICAL FRAILTY DESCRIBED IN CMS-2454-IFC
GENERAL DISCUSSION ON HEALTH COVERAGE REFORM
GENERAL DISCUSSIONS PREVENTING FUTURE CUTS TO HEALTHCARE IN POTENTIAL RECONCILIATION LEGISLATION
CFF SUBMITS COMMENTS TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) IN RESPONSE TO THEIR REQUEST FOR INFORMATION ON THE AFFORDABLE CARE ACT'S (ACA) ESSENTIAL HEALTH BENEFITS
CFF SUBMITS COMMENTS IN RESPONSE TO CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) INTERIM FINAL RULE ON THE MEDICAID WORK REPORTING REQUIREMENTS
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
DAVID |
ELIN |
|
|
|
MARY |
DWIGHT |
|
|
|
SCOTT |
SHERWOOD |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
GENERAL DISCUSSION ON DRUG PRICING REFORM
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
DAVID |
ELIN |
|
|
|
SCOTT |
SHERWOOD |
|
|
|
MARY |
DWIGHT |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SCI
16. Specific lobbying issues
(DRAFT) CLINICAL TRIAL MODERNIZATION ACT; ALL PROVISIONS
CFF SUBMITS COMMENTS IN RESPONSE TO AN REQUEST FOR INFORMATION (RFI) FROM THE FOOD AND DRUG ADMINISTRATION (FDA) ON EXPEDITED INVESTIGATIONAL NEW DRUG PILOT PROGRAM
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
MARY |
DWIGHT |
|
|
|
SCOTT |
SHERWOOD |
|
|
|
DAVID |
ELIN |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |